BridgeBio Pharma, Inc. (MUN:2CL)
62.18
+7.98 (14.72%)
At close: Dec 1, 2025
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M USD in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
41.57
Revenue / Employee
$484.63K
Employees
730
Market Cap
12.53B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kulmbacher Brauerei Aktien-Gesellschaft | 294.43M |
| MHP Hotel AG | 161.04M |
| Hoftex Group AG | 141.95M |
| BAVARIA Industries Group AG | 140.95M |
| Gesundheitswelt Chiemgau AG | 78.15M |
| Allgäuer Brauhaus AG | 39.94M |
| Landshuter Kunstmuehle AG | 24.18M |
| Münchener Tierpark Hellabrunn AG | 17.46M |
BridgeBio Pharma News
- 11 days ago - Wells Fargo Raises Price Target on BBIO, Maintains Overweight Rating | BBIO Stock News - GuruFocus
- 16 days ago - Pre-Market Most Active for Jan 16, 2026 : IBRX, TQQQ, TSLL, BBIO, NVO, T, MU, RKLZ, QXO, NOK, SMR, RDW - Nasdaq
- 16 days ago - BridgeBio Pharma prices $550M convertible bond offering - Seeking Alpha
- 16 days ago - BridgeBio Pharma Prices $550 Mln Of 0.75% Convertible Senior Notes Due 2033 - Nasdaq
- 16 days ago - BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire
- 17 days ago - BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 - GlobeNewsWire
- 19 days ago - BridgeBio Pharma Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
- 19 days ago - BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript - Seeking Alpha